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ABSTRACT: Background: Levodopa-carbidopa intes-
tinal gel (LCIG) is administered directly to the small intes-
tine of patients with advanced Parkinson’s disease (APD)
to help maintain stable plasma levodopa levels.
Objective: The objective of this study was to investigate
the effect of LCIG in reducing polypharmacy for the treat-
ment of APD.
Methods: The COmedication Study assessing Mono-
and cOmbination therapy with levodopa-carbidopa
inteStinal gel (COSMOS) is a large, real-world, multina-
tional observational study investigating comedication use
with LCIG. All enrolled patients had used LCIG for
≥12 months and data were collected cross-sectionally
(study visit) and retrospectively. The primary endpoint
was the percentage of patients using LCIG as mon-
otherapy (without add-on PD medications) at initiation
and at 3, 6, 9, and 12 months thereafter.
Results: Overall, 409 patients were enrolled from
14 countries and were treated with LCIG for a mean of
35.8  23.2 months. A total of 15.2% of patients initiated
LCIG as monotherapy and 31.7% were receiving mon-
otherapy at 12 months after initiation. The mean duration
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of LCIG monotherapy was 39.3  25.6 months. Use of
add-on medications decreased over time with all LCIG
regimens. From LCIG initiation to the patient visit, mean
off time decreased by 3.8, 4.6, and 3.9 hours/day for
LCIG monotherapy, LCIG daytime monotherapy, and
LCIG polytherapy groups, respectively, while duration of
dyskinesia decreased by 1.7, 2.0, and 1.9 hours/day,
respectively. Adverse events likely related to study treat-
ment occurred in 112 patients (27.4%) during LCIG
treatment.
Conclusions: LCIG is an effective long-term mon-
otherapy option with a positive risk–benefit profile and
contributes to reduced polypharmacy for patients
with APD. © 2021 The AbbVie Inc. Movement Disorders
published by Wiley Periodicals LLC on behalf of Interna-
tional Parkinson and Movement Disorder Society
Key Words: levodopa-carbidopa intestinal gel; mon-
otherapy; Parkinson’s disease; drug polytherapy; obser-
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Despite proven efficacy and widespread use of levo-
dopa for the treatment of Parkinson’s disease (PD), the
chemical properties of orally administered levodopa
include a short plasma half-life that leads to intermit-
tent receptor stimulation and subsequent fluctuations in
symptom control.1 As PD progresses, the therapeutic
window of levodopa treatment narrows and patients
experience intermittent motor and nonmotor symptoms
that require addition of drugs such as dopamine ago-
nists, catechol-O-methyl-transferase (COMT) inhibi-
tors, monoamine oxidase-B (MAO-B) inhibitors, or
amantadine.2 Poor treatment adherence is common
among patients with PD, possibly because of side
effects and/or drug–drug interactions from
comedications to help manage PD, other comorbidities,
or aspects of PD disease progression such as cognitive
decline and dysphagia.3-5 Therefore, the complex oral
drug regimens that are often used and frequently result
in inadequate symptom control can be particularly bur-
densome to patients with advancing PD, creating a par-
adoxical need to simplify drug regimen while the
disease progresses.6,7
Levodopa-carbidopa intestinal gel (LCIG) allows
individualized doses of levodopa to be infused continu-
ously into the small intestine to maintain physiological
dopamine levels.8 Evidence to date suggests LCIG is
clinically superior to oral polypharmacy in patients
with advanced PD (APD),9,10 and leads to clinically sig-
nificant improvements in dyskinesias, motor and non-
motor fluctuations, and health-related quality of life
(HRQoL) compared with immediate-release levo-
dopa.1,8,10-14 Such evidence suggests LCIG has the
potential to be administered as monotherapy, thereby
reducing pill burden, drug–drug interactions, side
effects, and poor treatment adherence. However, piv-
otal trials investigating LCIG required patients to take
LCIG monotherapy, which can affect real-world
outcomes.10,11
The effect of LCIG on reducing medication burden
has not been thoroughly investigated. In many studies,
LCIG titration and oral drug management is left to the
judgment of neurologists, which contribute to a lack of
standardization and reproducibility.10,11 Results from
1 phase 3 study demonstrated LCIG treatment reduced
the percentage of patients using COMT inhibitors,
dopamine agonists (DA), MAO-B inhibitors, and aman-
tadine over 12 months compared with baseline usage;
however, in that study, patients were required to stop
all treatments other than LCIG for the first 4 weeks of
the trial.11 Data from the Global LOng-term Registry
on efficacy and safety of LCIG In patients with APD in
routine care (GLORIA) demonstrated decreased use of
COMT inhibitors, DAs, MAO-B inhibitors, and aman-
tadine over 2 years of LCIG treatment compared with
use before LCIG initiation. Results showed 37% of
patients were taking LCIG monotherapy at 24 months,
whereas 57% who initiated LCIG as monotherapy were
taking LCIG monotherapy at 24 months, and 23% of
patients used LCIG monotherapy exclusively over the
entire 24-month period.15,16
Other device-aided therapies (DATs) include continu-
ous subcutaneous apomorphine infusion (CSAI) ther-
apy and deep brain stimulation (DBS), which have
shown promise as therapeutic options.17,18 However,
despite their effectiveness, results on their efficacy and
safety as monotherapies are limited.17-20
The COmedication Study assessing Mono- and cOm-
bination therapy with levodopa-carbidopa inteStinal gel
(COSMOS) is a large, multinational study, and the first
dedicated to investigating comedication use with LCIG
and the potential usability of LCIG as a monotherapy
by generating relevant data from routine clinical prac-
tice. Here, we report medication usage patterns over
12 months in patients with APD who were treated with
LCIG and compare attributes of LCIG therapy such as
use of concomitant medications versus monotherapy,
duration of LCIG monotherapy, and patient- and
physician-based predictors for achieving long-term
LCIG monotherapy.
Methods
Study Design and Setting
COSMOS (Clinicaltrials.gov identifier: NCT03362879)
was a multinational, retrospective, and cross-sectional,
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post-marketing observational study of patients with
APD who were treated with LCIG in routine clinical
care. Data were collected retrospectively from patient
medical records covering a period of at least
12 months since LCIG initiation and cross-sectionally
during a clinic visit.
Participants
Patients were eligible for inclusion if they were diag-
nosed with APD and received ongoing LCIG treatment
for ≥12 months and for ≥80% of days in the year pre-
ceding the study. Patients who had used LCIG therapy
as part of a previous or concurrent interventional trial
or were unable to complete study questionnaires were
excluded. Written informed consent was obtained by
each patient or legal authorized representative before
any data collection.
Variables and Data Sources
All clinical data obtained at the patient visit or from
medical records were entered into a web-based elec-
tronic data capture system for analysis.
Patient Demographics and Disease
Characteristics
During the study visit, the physician collected current
patient demographic information and socio-
demographic information both current to the visit and
from before initiation of LCIG. These data included
patient PD status based on Unified Parkinson’s Disease
Rating Scale (UPDRS) categories I–V, and Mini-Mental
State Examination (MMSE) scores. Patients or care-
givers were asked to state their overall preference for
LCIG as a monotherapy compared with LCIG with
add-on PD medication. Medical history was recorded
based on available information in patient medical
records and included PD phenotype, disease and symp-
tom chronology, time spent in the “off” state and the
“on” state with troublesome/nontroublesome dyskine-
sia, presence of motor and nonmotor PD symptoms,
UPDRS scores, modified Hoehn and Yahr stage
(UPDRS part V) ratings, and comorbidities related to
PD as judged by the physician at the time the record
was taken. Information on PD-related treatment (medi-
cation or DATs) from just before LCIG initiation was
also collected.
Treatments
Patients were stratified by LCIG treatment regimen
into 3 groups based on their treatment regimen at
12 months of therapy; (1) “LCIG monotherapy,”
defined as use of LCIG only with no add-on PD medi-
cations; (2) “LCIG daytime monotherapy,” defined as
LCIG with add-on PD medications used in the evening
after the daily LCIG infusion hours are completed; and
(3) “LCIG polytherapy,” defined as LCIG with add-on
medications at any time, including during LCIG infu-
sion hours.
Primary Endpoint
The primary endpoint was the percentage of patients
receiving LCIG monotherapy immediately after LCIG
initiation (after permanent system placement) and at
3, 6, 9, and 12 months after LCIG initiation.
Secondary Analyses
Secondary objectives included describing LCIG treat-
ment settings, analyzing patterns of add-on medication
use during LCIG treatment, assessing clinical outcomes
between treatment groups, and examining predictors of
LCIG monotherapy regimen versus LCIG with add-on
medication. Clinical characteristics such as duration of
dyskinesia and off time from the day before the study
visit, and UPDRS, nonmotor symptom scale (NMSS),
PDSS-2, and 8-item PD Questionnaire (PDQ-8) scores
at the patient visit were also analyzed.
Safety
Data from safety assessments previously collected
from healthcare professionals for other purposes were
used to document adverse events (AEs) that had a rea-
sonable possibility of being causally related to the treat-
ment drug or device.
Statistical Methods
Sample size was determined based on predefined pre-
cision of the estimators, expressed as the maximum
length of the corresponding two-sided 95% confidence
intervals (CIs). A sample of least 385 evaluable patients
was considered necessary to achieve a precision of
5% (ie, CIs ≤10%) and considering an underlying
percentage of 50% (ie, the percentage that leads to the
largest sample size).
Data collected from patient medical records and the
single-study visit are presented using descriptive statis-
tics. All results are expressed as mean  SD unless oth-
erwise stated. Two-sided 95% CIs were calculated for
primary and secondary endpoints defined by propor-
tions. Logistic regression was applied to investigate the
impact of potential prognostic factors for LCIG mon-
otherapy, including demographic variables, baseline
disease characteristics at LCIG initiation, and physician
and study site characteristics. All statistical analyses
were performed using SAS version 9.4 (SAS Institute,
Cary, NC).
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Results
Participants
A total of 409 patients from 49 sites in 14 countries
were included in the analysis. These sites treat a mean
of 730.3  768.8 patients with PD/APD annually; the
average frequency of routine visits for patients with
APD who were receiving DAT was 4.3 visits per year.
A total of 74 neurologists participated in the study and
71.4% of the 56 physicians who stated a preference
“preferred LCIG as monotherapy versus polytherapy.”
Most patients were male (65.3%) with a mean age of
66.5  7.8 years, UPDRS total score of 57.7  24.5,
and MMSE score of 27.5  2.8 before LCIG initiation
(Table 1). Baseline characteristics were generally well
matched between treatment groups (Table 1;
Supplementary Table S1), although the UPDRS Part III
score and time between PD diagnosis and LCIG initia-
tion were significantly increased in the LCIG poly-
therapy group compared with the LCIG monotherapy
group (Table 1). The primary reasons for LCIG initia-
tion were disabling motor fluctuations (n = 375;
91.7%) and decreased quality of life (n = 231; 56.5%)
(Supplementary Table S2). At the patient visit, the mean
duration of LCIG therapy among patients was
35.8  23.2 months (Supplementary Table S3).
TABLE 1. Demographics and baseline characteristics
LCIG monotherapya N = 120 LCIG daytime monotherapya N = 94 LCIG polytherapya N = 164 Total population N = 409
Description n % n % n % n %
Sex
Female 45 37.5 28 29.8 60 36.6 142 34.7
Male 75 62.5 66 70.2 104 63.4 267 65.3
n mean  SD n mean  SD n mean  SD n mean  SD
Age, at LCIG initiation, y 118 66.4  8.2 94 67.8  7.4 164 65.9  7.8 389 66.5  7.8
Duration of “off” period,b h 89 5.7  3.3 66 6.7  4.4 110 6.1  3.3 277 6.1  3.6
Duration of dyskinesia,b h 85 3.3  2.9 59 4.6  3.5 110 3.8  3.4 268 3.7  3.4
Time from PD diagnosis toc:
LCIG initiation, y 118 12.0  5.1 94 12.7  4.8 164 13.5  5.8d 390 12.8  5.4
Motor fluctuation onset, y 119 7.3  3.4 92 7.1  3.6 156 7.5  4.1 396 7.3  3.7
Morning akinesia, y 68 7.6  3.9 62 7.2  4.0 124 8.0  4.1 268 7.7  4.1
Wearing off, y 105 7.5  3.5 87 7.2  3.6 150 7.8  4.3 364 7.5  4.0
Dyskinesia, y 89 8.1  3.5 82 8.0  3.9 135 9.0  4.6 326 8.4  4.2
MMSE total score 74 27.4  3.1 46 26.6  2.7 80 28.0  2.7 222 27.5  2.8
UPDRS total score 35 58.2  22.9 33 55.5  26.6 45 60.8  24.7 118 57.7  24.5
Part I 34 4.5  2.5 31 4.1  2.9 44 4.6  2.5 112 4.4  2.6
Part II 43 17.0  8.3 36 15.4  6.9 51 17.5  8.1 135 16.6  7.8
Part III 54 26.8  12.5 48 28.3  12.9 82 33.9  17.8e 190 30.1  15.3
Part IV 43 8.2  5.1 37 8.5  4.6 62 9.9  6.0 147 8.8  5.4
PD medication before LCIG initiation, n (%)
Any medication 100 83.3 79 84.0 141 86.0 329 80.4
Levodopaf 91 75.8 78 83.0 132 80.5 309 75.6
DA 40 33.3 41 43.6 55 33.5 139 34.0
MAO-B inhibitors 27 22.5 22 23.4 25 15.2 74 18.1
COMT inhibitors 13 10.8 17 18.1 25 15.2 56 13.7
NMDA antagonists 13 10.8 19 20.2 16 9.8 51 12.5
APO injection 0 0 0 0 7 4.3 7 1.7
APO CI 1 0.8 1 1.1 1 0.6 3 0.7
Anticholinergics 1 0.8 2 2.1 6 3.7 9 2.2
Other 0 0 0 0 6 3.7 6 1.5
Symptoms at LCIG initiation, n (%)
Hallucination 1 0.8 2 2.1 4 2.4 7 1.7
Sleep disorders 29 24.2 22 23.4 38 23.2 91 22.2
Any impulsive-compulsive disorder 21 18.9 18 20.5 31 20.9 71 18.9
Previous deep brain stimulation 2 1.7 1 1.1 7 4.3 11 2.7
aPatients were grouped by their treatment regimen at 12 months, including 31 patients with inconclusive/missing treatment regimen data.
bHours during the day before the clinical visit as reported by the patient.
cRestricted to patients with these conditions.
dP < 0.05 vs. LCIG monotherapy.
eP < 0.05 vs. before LCIG initiation.
fLevodopa use included levodopa/carbidopa, levodopa/carbidopa/entacapone, and/or levodopa/benserazide.
Abbreviations: APO, apomorphine; CI, continuous infusion; COMT, catechol-O-methyl transferase; DA, dopamine agonist; LCIG, levodopa-carbidopa intestinal
gel; MAO-B, monoamine oxidase-B; MMSE, Mini-Mental State Examination; NMDA, N-methyl-D-aspartate; PD, Parkinson’s disease; SD, standard deviation;
UPDRS, Unified Parkinson’s Disease Rating Scale.
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Study patients were receiving LCIG monotherapy
(n = 120), LCIG daytime monotherapy (n = 94), or
LCIG polytherapy (n = 164) 12 months after LCIG ini-
tiation. Patients in the LCIG monotherapy group were
receiving monotherapy for a mean of
30.7  20.4 months and were receiving any LCIG regi-
men for 39.3  25.6 months, which was significantly
longer than the duration of any LCIG regimen for
patients in the LCIG daytime monotherapy group
(31.8  22.3 months; P < 0.05), but not in the LCIG
polytherapy group (35.7  21.9 months; P = 0.428).
LCIG titration was achieved most rapidly for patients
in the LCIG monotherapy group (6.0  3.4 days),
which was significantly decreased compared with LCIG
daytime monotherapy patients (8.8  6.2 days;
P < 0.001; Supplementary Table S3).
Primary Endpoint
The percentage of patients treated with LCIG mon-
otherapy increased from 15.2% (n = 54/356) at LCIG
initiation to 31.7% (n = 120/378) at 12 months,
whereas 13.2% (n = 47/356) of patients initiated treat-
ment with LCIG daytime monotherapy, which
increased to 24.9% (n = 94/378) at 12 months
(Fig. 1A). Therefore combined, the LCIG monotherapy
group and LCIG daytime monotherapy group com-
prised 28.4% of patients at baseline and 56.6% of
patients at month 12. LCIG polytherapy was most
common, with 71.6% of patients (n = 255/356) initiat-
ing LCIG therapy with this regimen; however, usage
decreased notably by month 3 to 42.8% of patients
(n = 158/369), then remained stable until month
12 (43.4% [n = 164/378]; Fig. 1A).
FIG. 1. Percentages of patients taking levodopa-carbidopa intestinal gel (LCIG) monotherapy at indicated time points (A). Number of pills per day of
add-on Parkinson’s disease medication by treatment group over time (B).
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Secondary Analyses
Add-on PD Medication Use by Class
The percentages of patients using add-on PD medica-
tion by class and the LCIG treatment regimen are pres-
ented in Figure 2 and Supplementary Table S4. The
numbers of patients using DA, COMT inhibitor, and
MAO-B inhibitors decreased over time in both the
LCIG monotherapy and LCIG daytime monotherapy
groups, whereas only COMT inhibitors decreased
among patients in the LCIG polytherapy group. As
expected, LCIG initiation was the most common reason
for discontinuation of add-on medications (73.3% of
patients; not shown). Most patients in the LCIG mon-
otherapy group (93.8%) and LCIG daytime mon-
otherapy group (73.8%) discontinued DA, MAO-B,
and COMT inhibitor use within 3 months of LCIG ini-
tiation. No percentage increases in DA, MAO-B, and
COMT inhibitor use were observed in any treatment
group after 3 months of LCIG therapy (Fig. 2). Before
LCIG initiation, the mean numbers of pills per day of
all add-on medications were 9.2  6.6 for LCIG mon-
otherapy, 11.1  6.7 for LCIG daytime monotherapy,
and 11.7  9.2 for LCIG polytherapy groups. At
month 12, the corresponding values were 0, 1.2  0.4,
and 3.1  2.6 pills per day, respectively, with a statisti-
cally significant difference from baseline in all groups
(Fig. 1B).
Overall Medication Needs
At LCIG initiation, the levodopa equivalent daily dose
(LEDD) for the LCIG daytime monotherapy group
(2583.0  922.6) and LCIG polytherapy group
(2630.8  1099.4) was significantly higher than the
LEDD in the LCIG monotherapy group (2266.6  929.7;
P < 0.05; Supplementary Fig. S1A). Similar results
occurred at 12 months when the LEDD of the LCIG
daytime monotherapy and LCIG polytherapy groups
were 2227.4  614.5 and 2331.0  879.7, respec-
tively, versus 1834.6  793.1 for LCIG monotherapy
group (both P < 0.0001). The LEDD for add-on PD
medications decreased from initiation to month
12 overall; however, the LEDD remained significantly
increased for the LCIG daytime monotherapy and
LCIG polytherapy groups compared with the LCIG
monotherapy group at all time points after LCIG initi-
ation (Supplementary Fig. S1B).
For all patients, the daily LCIG dose was similar at
12 months versus at initiation (1384  520 mg/day
and 1312  498 mg/day, respectively). Yet, patients in
the LCIG daytime monotherapy group had higher
daily doses of LCIG than did patients in the LCIG
monotherapy group at initiation (1388  444 mg/day
vs. 1242  506 mg/day; P < 0.01) and at 12 months
(1458  414 mg/day vs. 1326  568 mg/day; P < 0.01)
(Supplementary Fig. S1C).
FIG. 2. Percentages of patients with reported Parkinson’s disease medication usage before initiation of levodopa-carbidopa intestinal gel (LCIG) and as
add-on therapy over time by class. All patients (A), LCIG monotherapy (B), LCIG daytime monotherapy (C), and LCIG polytherapy (D). “Levodopa” indi-
cates oral formulations. COMT, catechol-O-methyl-transferase; MAO-B, monoamine oxidase-B, NMDA, N-methyl D-aspartate.
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Motor and Nonmotor Symptoms
In all groups, off time and dyskinesia duration were
reduced at the patient visit compared with LCIG initia-
tion, with no significant differences between groups
(Table 2). The mean number of motor symptoms
decreased from 6.6  2.1 at LCIG initiation to
5.8  2.4 at the patient visit for all patients
(P < 0.0001). The proportion of patients who experi-
enced rigidity, tremor, dystonia/cramps, gait impair-
ment, balance problems, hypophonia, dysphagia,
nocturnal/morning akinesia, and freezing of gait
showed significant decline at the patient visit compared
with LCIG initiation in all treatment groups
(P < 0.0001). Motor symptoms were similarly reduced
from the initiation of LCIG to the patient visit in all
treatment groups, although patients in the LCIG mon-
otherapy group showed significantly greater reductions
in nocturnal/morning akinesia versus those in the LCIG
daytime monotherapy group (20.8% reduction
vs. 11.7% reduction; P = 0.0099) and freezing of gait
versus those in the LCIG polytherapy group (14.2%
reduction vs. 0% reduction; P = 0.0036;
TABLE 2. Unified Parkinson’s Disease Rating Scale, Non-Motor Symptoms Scale, Parkinson’s Disease Sleep Scale 2,
Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease Rating Scale, and 8-item Parkinson’s Disease
Questionnaire scores at the patient visit
Mean  SD
LCIG monotherapy N = 120
LCIG daytime
monotherapy N = 94 LCIG polytherapy N = 164 Total population N = 409
n Result n Result n Result n Result
UPDRS total score 120 54.8  24.5a 94 54.8  20.3 164 57.2  23.0 408 56.2  23.6
Part I 120 3.6  2.9 94 3.4  2.6 164 3.6  2.4a 409 3.5  2.6
Part II 120 16.8  8.3 94 17.3  7.4 164 17.6  7.9 409 17.4  8.0
Part III 120 29.2  13.6 94 28.2  12.2 164 30.1  13.6 408 29.7  13.7
Part IV 120 5.2  3.6b 94 5.9  3.1b,d 164 5.9  3.5c 409 5.6  3.4c
Dyskinesias and dystonia, score 120 2.5  2.4 94 2.9  2.0 164 2.8  2.3 409 2.7  2.3
Motor fluctuations, score 120 1.8  1.5 94 2.0  1.3 164 2.3  1.4d 409 2.0  1.5
Other complications, score 120 0.9  0.9 94 1.0  0.9 164 0.8  0.9 409 0.8  0.9
Dyskinesias duration during the day, h 120 1.6  2.6 93 2.5  2.8d 163 1.8  2.4d 404 1.8  2.5
Change from pre-LCIG initiation 85 −1.7  2.9 59 −2.0  4.4 110 −1.9  3.8 267 −1.8  3.6
“Off” time during waking day, h 120 2.1  3.6 92 1.9  2.2 162 2.3  3.1a 403 2.1  3.1
Change from pre-LCIG initiation 89 −3.8  4.4 64 −4.6  4.3 110 −3.9  4.2 275 −4.0  4.3
Duration of dyskinesias or “off”
statee during waking day, h
120 3.6  5.0 92 4.4  4.1d 162 4.1  4.7 402 4.0  4.6
Change from pre-LCIG initiation 83 −5.8  4.9 56 −6.6  6.1 105 −6.0  6.4 255 −6.0  5.7
NMSS total score 120 58.2  45.4 94 60.8  38.1 160 57.5  41.4 404 57.6  42.2
Cardiovascular including falls 120 2.2  3.4 94 1.7  3.4 164 1.9  3.1 409 1.9  3.2
Sleep/fatigue 120 9.7  8.7 94 9.4  8.3 164 9.6  8.2 409 9.5  8.4
Mood/cognition 120 11.8  14.7 94 11.5  14.9 164 9.1  11.0 409 10.5  13.3
Perceptual problems/hallucinations 120 2.2  4.0 94 1.4  3.1 164 1.9  4.0 409 1.8  3.7
Attention/memory 120 6.8  8.7 94 6.5  7.2 164 6.9  8.5 409 6.6  8.2
Gastrointestinal tract 120 5.0  6.1 94 5.7  7.0 164 6.1  7.4 409 5.6  6.8
Urinary 120 9.0  8.9 94 11.3  9.2 164 10.7  10.0 409 10.3  9.4
Sexual function 120 4.5  7.3 94 4.5  6.6 160 3.2  5.8 404 3.7  6.4
Miscellaneous 120 7.1  8.5 94 8.8  7.9d 164 8.4  9.3 409 8.0  8.7
QUIP-RS total score 112 12.6  13.9 91 11.4  11.8 154 11.2  14.5 387 11.5  13.4
Gambling 117 0.7  1.9 94 0.6  1.7 163 0.8  2.2 404 0.7  1.9
Sex 116 1.8  2.9 93 1.9  3.2 160 1.9  2.8 400 1.8  2.9
Buying 117 1.6  2.7 94 1.8  2.9 162 1.5  2.6 404 1.6  2.7
Eating 117 2.3  3.2 94 2.1  2.8 160 2.0  3.2 402 2.1  3.1
Hobbyism/punding 116 4.9  6.2 93 3.9  4.5 158 3.8  5.2 398 4.1  5.3
Medication use 116 2.4  3.4 92 1.3  2.2 161 1.8  3.5d 400 1.8  3.1
Total ICD score 114 5.9  7.3 93 6.4  7.3 158 6.0  8.6 395 6.0  7.8
PDSS-2 total score 112 19.6  11.0 90 19.5  10.6 152 21.6  10.8 383 20.6  10.8
PDQ-8 summary index scores 119 41.5  17.7 93 36.5  18.1 161 40.2  18.3 404 40.3  18.2
aP < 0.05.
bP < 0.001.
cP < 0.0001 vs. baseline.
dP < 0.05 vs. LCIG monotherapy.
eChange of the duration of dyskinesias or “off” state duration should be considered additional “on time.”
Abbreviations: ICD, impulsive-compulsive disorder; LCIG, levodopa-carbidopa intestinal gel; NMSS, Non-Motor Symptoms Scale; PD, Parkinson’s disease;
PDSS-2, PD Sleep Scale 2; PDQ-8, 8-item PD Questionnaire; QUIP-RS, Questionnaire for Impulsive-Compulsive Disorders in PD Rating Scale; UPDRS, Unified
PD Rating Scale.
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Supplementary Fig. S2). The percentage of patients who
experienced nonmotor symptoms of anxiety, pain,
depression, and constipation decreased significantly
from the initiation of LCIG to the patient visit, whereas
the percentages of patients who experienced cognitive
impairment, apathy, fatigue, urinary symptoms, and
orthostatic hypotension increased significantly over that
time (all P < 0.001; Supplementary Fig. S2). The total
NMSS score, or any domain scores, were not signifi-
cantly different between treatment groups, and no sig-
nificant differences between treatment groups were
observed in UPDRS total score, PDSS-2 total score,
Questionnaire for Impulsive-Compulsive Disorders in
Parkinson’s Disease Rating Scale total score, and
PDQ-8 summary index scores (Table 2).
Predictors of Combined LCIG Monotherapy
Significant predictors of LCIG monotherapy use at
12 months after initiation were treatment with DA
before LCIG initiation versus no prior DA treatment
(odds ratio [OR], 1.743 [95% CI, 1.094, 2.777];
P = 0.0194), patient visits to their physician ≥3 ver-
sus <3 times/year while receiving DAT (OR, 2.297
[95% CI, 1.178, 4.478]; P = 0.0146), and approximate
number of patients with APD treated with LCIG annu-
ally by the physician (OR, 1.019 [95% CI, 1.000,
1.038]; P = 0.0489; Supplementary Table S5). Other
variables that predicted use of LCIG monotherapy were
lower number of motor symptoms (OR, 0.828 [95%
CI, 0.714, 0.960]; P = 0.0125), and lower gross
national income of the treatment site location (OR,
0.976 [95% CI, 0.958, 0.994]; P = 0.0101).
Safety
A total of 274 AEs likely related to study treatment
occurred in 112 patients (27.4%) from LCIG initiation to
the patient visit. The most common AEs reported were
stoma site infection (n = 11; 2.7%), dyskinesia (n = 9;
2.2%), and device malfunction (n = 8; 2.0%). Neuropathies
occurred in 6 patients (1.5%): polyneuropathy in 4 patients
(1.0%), and 1 patient (0.2%) each was reported with demy-
elinating polyneuropathy and peripheral neuropathy. A
decrease in vitamin B6 was reported for 1 patient (0.2%)
and decreased weight for 5 patients (1.2%).
Discussion
In this observational study, the percentages of
patients with APD treated with LCIG monotherapy
(either with no add-on medications or with add-on
medications outside LCIG infusion hours) increased
between treatment initiation and month 3 and
remained relatively stable through month 12. LCIG
with add-on medications (LCIG polytherapy) was the
most frequently used treatment regimen, although the
frequency of prescribing add-on medications decreased
considerably between LCIG initiation and month
3, after which usage remained stable. Titration of LCIG
was achieved most rapidly in the LCIG monotherapy
group, potentially because most were able to discon-
tinue DA, MAO-B, and COMT inhibitor therapy
quickly (within 3 months of LCIG therapy, without
increase after 3 months of LCIG therapy), possibly
because part of the titration was performed during the
naso-jejunal test phase. Moreover, during the 12-month
observation period, COMT inhibitor use decreased
within all LCIG treatment groups. All groups demon-
strated a significant improvement in off time and dyski-
nesia, and we did not observe any clinically significant
differences between groups in symptomatic outcomes,
as rates of off time and dyskinesia decreased by month
12 compared with LCIG initiation in all treatment
groups. Use of LCIG monotherapy was predicted by
previous DA usage, more frequent physician visits (≥3
times in a year), and number of motor symptoms,
suggesting advancing disease may predict use of LCIG
monotherapy; this supports the notion that DAs are less
tolerated in patients who need more frequent evalua-
tions. Most physicians preferred to prescribe LCIG
monotherapy to simplify the medication regimen after a
DAT was implemented and to reduce the pill burden.
This primary analysis of the COSMOS study repre-
sents the first investigation dedicated to add-on PD
medication use and monotherapy before and during
LCIG therapy. Our findings are supported by results of
a post hoc analysis from the multinational GLORIA
registry study that monitored LCIG therapy over
24 months in patients with APD. In that study, between
36% and 40% of patients were treated with LCIG
monotherapy at all time points, and at the end of
24 months, 23% of patients (n = 59) had used LCIG
monotherapy exclusively over the full observation
period.16 In the GLORIA study, the proportion of
patients who used oral levodopa, DAs, COMT inhibi-
tors, MAO-B inhibitors, and the N-methyl-D-aspartate
receptor antagonist amantadine decreased during LCIG
therapy compared with baseline.15 Other results that
support our findings include those from a 12-month,
phase 3, single-arm trial, where percentages of patients
using add-on DA decreased from 55.4%–12.7%,
COMT inhibitors from 28.2%–3.7%, MAO-B inhibi-
tors from 12.7%–1.5%, and amantadine from 29.9%–
9.6%; whereas the 26.6% of patients who were taking
monotherapy at baseline increased to 76.5%, this
increased use included those patients who received LCIG
with or without oral supplementation.11 However, it is
notable that patients enrolled in that study were required
to stop all non-LCIG PD medications for the first
4 weeks of LCIG treatment, which does not occur in
clinical practice, suggesting rates of add-on medication
use in the COSMOS and GLORIA studies more closely
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represent real-world clinical treatment than medication
dosing in a phase 3 clinical trial. Both the COSMOS and
GLORIA studies presented favorable data on symptom-
atic outcomes, supporting the feasibility of using long-
term LCIG monotherapy in selected patients.16
Poor treatment adherence is a pervasive issue among
patients treated for PD, for whom up to 67% take
<80% of their prescribed medications.7 Lack of medica-
tion adherence often increases over time for several likely
reasons. First, patients with PD are susceptible to high
pill burden. In addition to standard dopaminergic medi-
cations that may be needed up to 10 times per day, more
than half of patients have multiple prescriptions for non-
motor symptoms and comorbidities.7 Unfortunately,
neurodegenerative processes that create the need for
higher quantities and more frequent medications underlie
progressive cognitive deficits that render the patient less
capable of managing increasingly complex regimens.
Further, patients with advancing PD can experience
problems such as difficulty swallowing and irregular gas-
tric emptying that negatively affect the ingestion and
absorption of oral medications.5,21 Poor treatment
adherence in PD may negatively impact patients both in
terms of motor and nonmotor complications, and in
HRQoL.22 Overall, in patients with PD, the fewer medi-
cations prescribed, the better the treatment adherence.23
A few studies have been performed to investigate the
need for add-on medications with DATs. Results from
investigations of CSAI revealed that, although use of this
treatment approach could significantly reduce the need
for oral levodopa, most patients continue to require oral
levodopa to achieve a full clinical effect.24,25 Similar find-
ings were observed in studies on DBS, which can signifi-
cantly reduce oral anti-PD medications for improving
motor function, yet evidence is lacking to support DBS as
long-term monotherapy.26,27 In our study, even though
nearly one-third of patients were taking LCIG mon-
otherapy at 12 months of LCIG treatment, no clinically
significant differences in symptomatic outcomes (off time
and dyskinesia) were apparent between groups receiving
LCIG monotherapy and groups that used LCIG and add-
on medications. These data suggest LCIG monotherapy
was as effective as LCIG plus add-on medication in con-
trolling symptoms, which could not be explained by any
remarkable differences in demographic or PD history
between groups. Therefore, when possible, LCIG mon-
otherapy is a valid solution for many patients with APD
to achieve similar symptom control as when using add-on
medications, while reducing PD-related pill burden.
A major strength of this study was use of real-world,
multinational, large-cohort clinical data on LCIG mon-
otherapy and add-on PD medication use. The study was
limited by partially retrospective data collection and
purely observational data, which resulted in missing data
for some analyses. Further, patients were grouped by
their status at month 12, so lack of randomization
precluded meaningful comparisons between groups.
Choice of medication regimen may have correlated with
disease severity, although no major differences in disease
characteristics between groups were apparent. We noted
in our study that patients with more severe disease
tended to remain on polytherapy. Further detailed analy-
sis may be required to clarify this observation. Finally,
our study only included patients treated with ongoing
LCIG and able to sustain LCIG treatment for at least
12 months; therefore, results are not representative of all
patients who initiate LCIG. This requirement, in addi-
tion to limiting AEs to those related to LCIG treatment,
likely contributed to the low frequency of AEs in this
study versus the rates of AEs in phase 3 studies.28
Conclusion
The data from this observational, real-world study in
patients with APD provided evidence that LCIG mon-
otherapy is a feasible and effective long-term treatment
option for symptoms of APD. Patients who reduced their
pill intake by receiving LCIG as monotherapy experi-
enced similar clinical benefits as patients who continued
to take add-on medications. Yet patients with preserved
combination therapy also experienced considerable
reductions in comedication use. The safety results were
consistent with the known profile of LCIG. These results
reveal LCIG monotherapy is an effective means to man-
age symptoms while reducing pill burden.
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